Increased expression of CD40 on bone marrow CD34+ hematopoietic progenitor cells in patients with systemic lupus erythematosus: Contribution to fas-mediated apoptosis

Arthritis and Rheumatism

Volumn 60, Issue 2, 2009, Pages 543-552

  Pyrovolaki, Katerina ^a   Mavroudi, Irene ^a   Sidiropoulos, Prodromos ^a   Eliopoulos, Aristides G ^a   Boumpas, Dimitrios T ^a   Papadaki, Helen A ^a,b  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; FAS ANTIGEN; FAS LIGAND;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL SURVIVAL; CLINICAL ARTICLE; COLONY FORMING CELL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; MALE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; ANTIGENS, CD34; ANTIGENS, CD40; ANTIGENS, CD95; APOPTOSIS; BIOLOGICAL MARKERS; BONE MARROW CELLS; CELL SURVIVAL; CELLS, CULTURED; CLONE CELLS; FAS LIGAND PROTEIN; FEMALE; HEALTH STATUS; HEMATOPOIETIC STEM CELLS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; STROMAL CELLS; YOUNG ADULT;

EID: 59649102736     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24257     Document Type: Article

References (39)

1. Ikehara S. Bone marrow transplantation: a new strategy for intractable diseases. Drugs Today (Barc) 2002;38:103-11.
2. Burt RK, Traynor AE, Craig R, Marmont AM. The promise of hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant 2003;31:521-4.
3. Dazzi F, van Laar JM, Cope A, Tyndall A. Cell therapy for autoimmune diseases. Arthritis Res Ther 2007;9:206.
4. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006;107:367-72.
5. Papadaki HA, Boumpas DT, Gibson FM, Jayne DR, Axford JS, Gordon-Smith EC, et al. Increased apoptosis of bone marrow CD34(+) cells and impaired function of bone marrow stromal cells in patients with systemic lupus erythematosus. Br J Haematol 2001;115:167-74.
6. Westerweel PE, Luijten RK, Hoefer IE, Koomans HA, Derksen RH, Verhaar MC. Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus. Ann Rheum Dis 2007;66:865-70.
7. Sun LY, Zhou KX, Feng XB, Zhang HY, Ding XQ, Jin O, et al. Abnormal surface markers expression on bone marrow CD34(+) cells and correlation with disease activity in patients with systemic lupus erythematosus. Clin Rheumatol 2007;26:2073-9.
8. Statkute L, Verda L, Oyama Y, Traynor A, Villa M, Shook T, et al. Mobilization, harvesting and selection of peripheral blood stem cells in patients with autoimmune diseases undergoing autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2007;39:317-29.
9. Papadaki HA. Autoreactive T-lymphocytes are implicated in the pathogenesis of bone marrow failure in patients with systemic lupus erythematosus. Leuk Lymphoma 2003;44:1301-7.
10. Fiumara P, Younes A. CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies. Br J Haematol 2001;113:265-74.
11. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001;58:4-43.
12. Koshy M, Berger D, Crow MK. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996;98:826-37.
13. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996;97:2063-73.
14. Yellin MJ, Thienel U. T cells in the pathogenesis of systemic lupus erythematosus: potential roles of CD154-CD40 interactions and costimulatory molecules. Curr Rheumatol Rep 2000;2:24-31.
15. Yazdany J, Davis J. The role of CD40 ligand in systemic lupus erythematosus. Lupus 2004;13:377-80.
16. Vakkalanka RK, Woo C, Kirou KA, Koshy M, Berger D, Crow MK. Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum 1999;42:871-81.
17. Kato K, Santana-Sahagun E, Rassenti LZ, Weisman MH, Tamura N, Kobayashi S, et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 1999;104:947-55.
18. Goules A, Tzioufas AG, Manousakis MN, Kirou KA, Crow MK, Routsias JG. Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. J Autoimmun 2006;26:165-71.
19. Funakoshi S, Longo DL, Beckwith M, Conley DK, Tsarfaty G, Tsarfaty I, et al. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 1994;83:2787-94.
20. Baker MP, Eliopoulos AG, Young LS, Armitage RJ, Gregory CD, Gordon J. Prolonged phenotypic, functional, and molecular change in group I Burkitt lymphoma cells on short-term exposure to CD40 ligand. Blood 1998;92:2830-43.
21. Von Leoprechting A, van der Bruggen P, Pahl HL, Aruffo A, Simon JC. Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res 1999;59:1287-94.
22. Georgopoulos NT, Steele LP, Thomson MJ, Selby PJ, Southgate J, Trejdosiewicz LK. A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation. Cell Death Differ 2006;13:1789-801.
23. Afford SC, Randhawa S, Eliopoulos AG, Hubscher SG, Young LS, Adams DH. CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface fas ligand expression and amplifies fas-mediated hepatocyte death during allograft rejection. J Exp Med 1999;189:441-6.
24. Eliopoulos AG, Davies C, Knox PG, Gallagher NJ, Afford SC, Adams DH, et al. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol 2000;20:5503-15.
25. Zhou F, Ajuebor MN, Beck PL, Le T, Hogaboam CM, Swain MG. CD154-CD40 interactions drive hepatocyte apoptosis in murine fulminant hepatitis. Hepatology 2005;42:372-80.
26. Lee JK, Seki N, Sayers TJ, Subleski J, Gruys EM, Murphy WJ, et al. Constitutive expression of functional CD40 on mouse renal cancer cells: induction of Fas and Fas-mediated killing by CD40L. Cell Immunol 2005;235:145-52.
27. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
28. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang DH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
29. Philpott NJ, Turner AJ, Scopes J, Westby M, Marsh JC, Gordon-Smith EC, et al. The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood 1996;87:2244-51.
30. Coutinho LH, De Wynter EA, Will A, Testa NG. Clonal and long-term cultures using human bone marrow. In: Testa NG, Milineux G, editors. Haemopoiesis: a practical approach. Oxford: Oxford University Press; 1993. p. 75-106.
31. Toure R, Kheadr E, Lacroix C, Moroni O, Fliss I. Production of antibacterial substances by bifidobacterial isolates from infant stool active against Listeria monocytogenes. J Appl Microbiol 2003;95:1058-69.
32. Nagafuji K, Shibuya T, Harada M, Mizuno S, Takenaka K, Miyamoto T, et al. Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells. Blood 1995;8:883-9.
33. Papadaki HA, Kritikos HD, Gemetzi C, Koutala H, Marsh JC, Boumpas DT, et al. Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor α-mediated effect. Blood 2002;99:1610-9.
34. Voulgarelis M, Giannouli S, Tasidou A, Anagnostou D, Ziakas PD, Tzioufas AG. Bone marrow histological findings in systemic lupus erythematosus with hematologic abnormalities: a clinicopathological study. Am J Hematol 2006;81:590-7.
35. Tagoe C, Shah A, Yee H, Belmont HM. Aplastic anemia in systemic lupus erythematosus: a distinct presentation of acquired aplastic anemia? J Clin Rheumatol 2001;7:377-83.
36. Burt RK, Fassas A, Snowden J, van Laar JM, Kozak T, Wulffraat NM, et al. Collection of hematopoietic stem cells from patients with autoimmune diseases. Bone Marrow Transplant 2001;28:1-12.
37. Tyndall A, Daikeler T. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Acta Haematol 2005;114:239-47.
38. Xerri L, Bouabdallah R, Devilard E, Hassoun J, Stoppa AM, Birg F. Sensitivity to Fas-mediated apoptosis is null or weak in B-cell non-Hodgkin's lymphomas and is moderately increased by CD40 ligation. Br J Cancer 1998;78:225-32.
39. Papadaki HA, Marsh JC, Eliopoulos GD. Bone marrow stem cells and stromal cells in autoimmune cytopenias. Leuk Lymphoma 2002;43:753-60.